Causes of failure in psychopharmacological treatment of panic disorder;Causas de fracaso en el tratamiento psicofarmacológico del trastorno por angustia

Actas Espanolas de Psiquiatria

Volumn 27, Issue 4, 1999, Pages 250-258

  Segui J ^c   Marquez M ^a   Canet, J ^b   Garcia L ^d  

^a Ctro Salud Mental Cerdanyola Valles   (Spain)

^b PSINEP   (Spain)

^c HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^d NONE

Author keywords

Panic disorder; Refractoriness

Indexed keywords

ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; DIAGNOSTIC ERROR; HUMAN; RECURRENT DISEASE; REVIEW; TREATMENT FAILURE;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DIAGNOSTIC ERRORS; HUMANS; RECURRENCE; TREATMENT FAILURE;

EID: 0033162211     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, et al. The Cross-national epidemiology of panic disorder. Arch Gen Psychiatry 1997;54:305-9.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Association; 1994.
3. Salvador L, Seguí J, Fernández-Cano P. Uso de servicios, efecto de compensación y costes del trastorno de pánico. Med Clin (Barc) 1994;103:287-92.
4. León AC, Olfson M, Portera L. Service utilization and expenditures for the treatment of panic disorder. Gen Hosp Psychiatry 1997;19:82-8.
5. Salvador-Carulla L, Seguí J, Fernández-Cano P, Canet J. Costs and Offset Effect in Panic Disorders. Br J Psychiatry 1995;166(Supl 27):223-8.
6. Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure and panic disorder. J Clin Psychiatry 1997;58(12):555-61.
7. Prien RF, Carpenter LL, Kupfer DJ, et al. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991;48: 796-800.
8. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991;48: 851-5.
9. Shear MK, Maser JD. Standardized assessment for panic disorder research. Arch Gen Psychiatry 1994;51: 346-54.
10. Seguí J. Fluoxetina y trastorno por angustia. Rev Psquiatría Fac Med Barna 1996;23(6):181-8.
11. Johnston DG, Troyer IE, Whitsett SF. Clomipramina treatment of agoraphobic women. Arch Gen Psychiatry 1988;45:453-9.
12. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway study of panic disorder I: clorimipramine and lofepramine in DSM III-R panic disorder: A placebo controlled trial. J Affect Dis 1992;25:63-76.
13. Glesecke-Mark E. Overcoming hypersensitivity to fluoxetine in a patient with panic disorder (letter). Am J Psychiatry 1990;147:532-3.
14. Gorman AM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the tratament of panic attacks. J Clin Psycopharmacol 1987;7:329-32.
15. Schneider FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psycopharmacol 1990;10:119-21.
16. Diez C, Rangil T, Prats M, Sánchez-Planell L. Fluoxetina como tratamiento del trastorno de angustia: estudio retrospectivo. Sevilla: Actas del Congreso Nacional de la Sociedad Española de Psiquiatría; 1995.
17. Sarah A, Halaris A. Panic attack precipitated by fluoxetine. J Neuropsychiatry Clin Neurosci 1989;1: 219-20.
18. Altshuler LL. Fluoxetine-associated panic attacks. J Clin Psychopharmacol 1994;14:433-4.
19. Seguí J, Salvador L, Canet J, Ortiz M. Tolerancia inicial y abandono precoz del tratamiento con paroxetina en el tratamiento del trastorno de pánico. C Med Psicosom 1995;36:74-8.
20. Aronson TA. A naturalistic study of imipramine in panic disorder and agoraphobia. Am J Psychiatry 1987; 144:1014-9.
21. Kahn RS, Van Praag HM, Wetzler S, Asnis GM, Barr C. Serotonin and anxiety revisited. Biol Psychiatry 1988;23:189-208.
22. Charney DS, Woods SW, Goodman WK, Heninger OR. Serotonin Function in anxiety II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjets. Psycopharmacologic 1987;92: 14-24.
23. Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety and discontinuance. Clonazepam panic disorder dose-response study group. J Clin Psychopharmacol 1997;17(5)390-400.
24. Noyes R Jr, Garvey MJ, Cook B, et al. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991;148: 517-23.
25. Hollander E, Cohen LJ. The assessment and treatment of refractory anxiety. J Clin Psychiatry 1994; 55(Supl 2):27-31.
26. Keller MB, Baker LA. The clinical course of panic disorder and depression. J Clin Psychiatry 1992;53 (Supl 3):5-8.
27. Keller MB, Yonkers KA, Warshaw MG, et al. Remision and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis 1994;182:290-6.
28. Seguí J, Salvador L, Garcia L, Canet J, Ortiz M. Subgrupos clínicos de trastorno por angustia: de la fenomenología a Ia agrupación diagnóstica. Actas Luso-Esp Neurol Psiquiatr 1998;26:65-73.
29. Seguí J, Salvador-Carulla L. Semiology and subtyping of panic disorder. Acta Psychiatr Scand 1998;97: 272-7.
30. Vollrath M, Angst J. Outcome of panic and depression in a seven-year follow-up: results of the Zurich study. Acta Psychiatr Scand 1989;80:591-6.
31. Uhde TW, Boulenger J, Roy-Byme PP, et al. Longitudinal course of panic disorder: clinical and biological considerations. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:39-51.
32. Sheehan DV, Ballenger J, Jacobson G. Treatment of endogenous anxiety with phobic, hysterical and hypocondriacal symptoms. Arch Gen Psychiatry 1980; 37:51-9.
33. Gloger S, Grunhaus L, Birmacher B, Troudart T. Treatment of spontaneus panic attacks with clomipramina. Am J Psychiatry 1981;38:1215-7.
34. Dunner DL, Ishiki D, Avery DH, et al. Effect of alprazolam and diazepam on anxiety and panic attacks: a controlled study. J Clin Psychiatry 1986;47:458-60.
35. Mavissakalian M, Perel JM. Imipramie in panic disorder with agoraphobia: dose-ranging and plaasma level response relationships. Am J Psychiatry 1995; 152:637-42.
36. Charney DS, Woods SWS, Goodman WIC, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam and trazodona. J Clin Psychiatry 1986;47:580-6.
37. Charney DS, Woods SWS. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418-23.
38. Ballanger JC, Burrow GD, Dupont RLJ, et al. Alprazolam in panic disorder: results from a multicenter trial, I: efficacy in short term treatment. Arch Gen Psychiatry 1988;45:413-22.
39. German JM. The use of newer antidepressants for panic disorder. J Clin Psychiatry 1997;58(Supl 14):54-8.
40. Lydiard RB, Ballanger JC. Antidepressants in panic disorder and agoraphobia. J Affect Dis 1987;13:153-68.
41. Frank E, Kupfer DJ, Perel JM, et al. Three years outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;1092-9.
42. Kupfer DJ, Frank E, Perel JM. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-73.
43. Roy-Byme PP, Cowley DS. Course and outcome in panic disorder: a review of recent follow-up studies. Anxiety 1995;1:151-60.
44. Pollack MH, Otto MN, Rosembaum JF, et al. Longuitudinal course of panic disorder: findings from the Massachusetts General Hospital naturalistic study. J Clin Psychiatry 1990;51(Supl A):12-6.
45. Noyes R, Reich J, Christiansen J, et al. Outcome of panic disorder: relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry 1990;47:809-18.
46. Coryell W, Endicott J, Andreasen N. Depression and panic attacks: the significance and overlap as reflected in folow-up and family study data. Am J Psychiatry 1988;145:508-10.
47. Maier W, Buller R. One year follow-up of panic disorder: outcome and prognostic factors. Eur Arch Psychiatry Neurol Sci 1988;238:105-9.
48. Nagy LM, Krystal JH, Woods SW, et al. Clinical and medication outcome after short-term alprazolam and behavioral group treatment of panic disorder: 2,5-year naturalistic follow-up study. Arch Gen Psychiatry 1986;46:993-9.
49. Noyes R, Perry P. Maintenance treatment with anti-depressants in panic disorder. J Clin Psychiatry 1990;51:2-30.
50. Noyes R, Garvey MJ, Cook BL, et al. Problems with tricyclic antidepressants use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry 1989;50(5):163-9.
51. Noyes R, Garvey MJ, Cook BL. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Dis 1989;16:249-57.
52. Shweizer E, Rickels K, Weiss S, et al. Maintenance drug treatment of panic disorder. I Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993; 50:51-60.
53. Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 1973;32: 237-54.
54. Mavissakalian M, Perel JM, De Groot C. Imipramine treatment of panic disorder with agoraphobia: the second time around. J Psychol Res 1993;27:61-8.
55. Seehan DV, Raj A. Benzodiacepine treatment of panic disorder. En: Noyes R, Roth M, Burrows GD, eds Handbook of Anxiety. Vol 4. The treatment of anxiety. New York: Elsevier; 1990. p. 169-206.
56. Burrows GD, Norman TR, Judd FK, et al. Short-acting versus long-acting benzodiazepines: discontinuation effects in panic disorders. J Psychiatry Res 1990;24 (Suppl 2):65-72.
57. DuPont RL, Swinson RP, Ballenger JC, et al. Discontinuation of alprazolam treatment in panic disorders. J Clin Psychopharmacol 1992;12:352-4.
58. Rickels K, Schweitzer E, Csanacosi Y, et al. Long term treatment of anxiety and risk of withdrawal: prospective comparison of cloracepate and buspirone. Arch Gen Psychiatry 1988;45:444-7.
59. Rosembaum JF. Treatment-resistant panic disorder. J Clin Psychiatry 1997;58(Suppl 2):61-4.
60. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behavior therapy for treatment refractory panic disorder. J Clin Psychiatry 1994;55(5):200-5.
61. Tiffon L, Coplan JD, Papp LA, Gorman JM. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Pcyhiatry 1994;55:66-9.
62. Schneider FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, Klein D. Fluoxetine in panic disorder. J Clin Psycopharmacol 1990;10:119-21.
63. Solyom L, Solyom C, Ledwidge B. Fluoxetine in panic disorder. Can J Psychiatry 1991;36(5):378-80.
64. Coplan JD, Tiffon L, Gorman JM. Therapeutic strategies for the patient with treatment-resistant anxiety. J Clin Psychiatry 1993;54(Supl):69-74.
65. Cournoyer J. Rapid response of a disorder to the addition of lithium carbonate: panic resistant to tricyclic antidepressants. Can J Psychiatry 1986;31(4): 335-8.
66. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994; 55(1):24-5.
67. Boerner RJ. Treatment refractory panic disorder-success of a combined treatment with imipramine, moclobemide and behavior therapy. Psychiatr Prax 1995;22(1):30-2.
68. Tesar GE, Rosenbaum JF. Successful use of clonazepam in patients with treatment-resistant panic disorder. J Nerv Ment Dis 1986;174(8):477-82.
69. Tesar GE, Rosembaum JF, Pollack, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52:69-76.
70. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13 (4):257-63.
71. Davidson JRT. Use of benzodiacepines in panic disorder. J Clin Psychiatry 1997;58(Supl 2):26-8.
72. Svebak S, Cameron A, Levander S. Clonazepam and imipramine in the treatment of panic attacks: a double-blind comparison of efficacy and side effects. J Clin Psychiatry 1990;51(Supl):14-7.
73. Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic disorder: a doubled-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14 (2):111-8.
74. Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment resistant panic disorder. J Psychiatry Neurosci 1992;17(2):78-80.
75. Dantendorfer K, Frey R, Maierhofer D, Saletu B. Sudden arousals from slow wave sleep and panic disorder: succesful treatment with anticonvulsants - a case report. Sleep 1996;19(9):744-6.
76. Hetem LA. Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder - a case report. J Clin Psychopharmacol 1996;16(1):77-8.
77. Gastfriend DR, Rosenbaum JF. Adjuntive buspirone in benzodiazepine treatment of four patients with panic disodrer. Am J Psychiatry 1989;146(7):914-6.
78. Keck P, Taylor V, Tugrul K, et al. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993;33:542-6.
79. Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998;43(1):73-7.
80. Geracioti TD. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56(9): 408-10.
81. Pollack MH, Worthington JJ, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32(4):667-70.
82. Demartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996;57(6):245-8.
83. Klein DF, Uhde T. Controlled study of verapamil for treatment of panic disorder. Am J Psychiatry 1988; 145:431-4.
84. Balon R, Ramesh C. Calcium channel blockers for anxiety disorders? Ann Clin Psychiatry 1996;8:215-20.
85. Pollard CA, Obermeier HJ, Cox GL. Inpatient treatment of complicated agoraphobia and panic disorder. Hosp Community Psychiatry 1987;38(9):951-8.